US-based Avenacy has announced the launch of its ready-to-use tranexamic acid in 0.7% sodium chloride injection in the U.S. market. This is a significant addition to the company's expanding portfolio of specialty injectable products. The announcement marks the company's 27th product launch since its founding in October 2023, highlighting its ongoing commitment to improving access to necessary pharmaceuticals.
The FDA-approved medicine CYKLOKAPRON® and the recently introduced tranexamic acid injection share the same active ingredient. It is recommended for short-term use in hemophiliac patients to reduce the need for replacement therapy before and after dental procedures like tooth extraction and to avoid bleeding. The tranexamic acid injection is delivered in cartons of 10 single-dose vials, each of which is a ready-to-use vial containing 1,000 mg per 100 mL (10 mg/mL).
Avenacy emphasized that the launch of this tranexamic acid injection aligns with its primary objective of improving patient safety and accelerating care delivery. To ensure accurate drug selection and administration, the business has incorporated unique packaging and labeling features. Additionally, these design elements are meant to help doctors ensure safe and efficient use in clinical settings.
According to Jeff Yordon, co-founder and CEO of Avenacy, the launch reflects the company’s commitment to addressing critical needs in the hospital and healthcare sector. He stated that the new offering may help physicians deliver care more efficiently while reducing preparation time and medication errors.
From a market perspective, the launch of this formulation aligns with an ongoing increase in demand for injectable drugs. Tranexamic acid injection sales in the United States were approximately $30.2 million for the 12 months ending March 2026. Notably, approximately $15 million of this total came from ready-to-use formulations, showing a significant preference for efficient and convenient medication delivery methods.
Even if the product has clear operational advantages, its long-term success will depend on how widely it is adopted in healthcare systems and how much demand there is for ready-to-use solutions. Simplified treatment alternatives are becoming increasingly important due to the complexity of hospital settings, and solutions such as this tranexamic acid injection are well-positioned to meet these needs.
The launch also highlights a broader trend in the pharmaceutical sector toward creating formulations that enhance safety and reduce preparation times. Ready-to-use injectable drugs are becoming a key area of focus for innovation and investment as providers seek to optimize workflows and reduce errors.
Hence, the launch of ready-to-use tranexamic acid injection is a smart move that strengthens its injectable range and meets important operational and clinical requirements. The company's ongoing growth is a commitment to providing critical, high-quality drugs that enhance patient care and the effectiveness of the healthcare system.
